Drug intelligence / Profile preview

AT-777

Development stage: Phase 1
Lead developer: Atea Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

AT-777 is an investigational small molecule inhibitor targeting the nonstructural protein 5A (NS5A) of the hepatitis C virus (HCV). It was developed by Atea Pharmaceuticals for the treatment of chronic hepatitis C infection. The drug acts by inhibiting HCV NS5A, a protein essential for viral replication and assembly, thereby reducing viral load in infected individuals. Clinical studies have evaluated its safety, tolerability, pharmacokinetics, and antiviral activity both as monotherapy in healthy subjects and in combination with other antivirals such as AT-527 in HCV-infected patients[1][2][6].

Targets

NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))

Beyond the preview

Go deeper on AT-777.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-777.

Explore the full profile